^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CXCL5 (Chemokine (C-X-C motif) ligand 5)

    i
    Other names: CXCL5, ENA-78, SCYB5, Chemokine (C-X-C motif) ligand 5
    2d
    Monocytes acquire a tumor-associated IL1B program upon encountering patient-derived colon cancer organoids. (PubMed, Oncoimmunology)
    In addition, our in vitro system allowed functional assessment of PDO-exposed monocytes demonstrating a compromised capacity to mount an inflammatory response upon TLR stimulation. Together, PDO-monocyte co-cultures offer a platform to dissect the interplay between cancer cells and monocytes, and advance our understanding of myeloid plasticity and function in cancer patients.
    Journal
    |
    CXCL5 (Chemokine (C-X-C motif) ligand 5) • IL1B (Interleukin 1, beta)
    6d
    Bone-on-leaf-chip for the study of lung cancer bone metastasis. (PubMed, Lab Chip)
    These cytokines can serve as potential biomarkers for assessing disease progression or providing a basis for developing new targeted therapies. Taken together, the successful construction and application of this leaf vein chip establish a versatile, mechanistically tractable platform for future drug screening, pathological analysis, and microenvironment-targeted strategies relevant to bone metastasis.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • VCAM1 (Vascular Cell Adhesion Molecule 1)
    6d
    Osteoblasts exert a pro-tumorigenic effect on breast cancer spheroids through CXCL5/CXCR2 signalling in two-dimensional and three-dimensional bone mimetic cultures. (PubMed, J R Soc Interface)
    We show that these effects depend on the CXCL5/CXCR2 signalling axis. Taken together, we demonstrate that osteoblasts enhance cancer growth in a bone metastatic niche and that this effect is reversible with CXCL5/CXCR2 inhibition.
    Journal
    |
    CXCL5 (Chemokine (C-X-C motif) ligand 5) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
    7d
    Coordinated DNA methyltransferase 3A and methyltransferase-like 7A activity reprograms the tumor microenvironment through discoidin domain receptor 1 signaling. (PubMed, Cancer Biol Med)
    DNMT3A and METTL7A were shown to cooperatively regulate DDR1 via DNA/m6A methylation, which drives Treg-mediated immune suppression and recurrence. This study provided novel insights and therapeutic targets for breast cancer prognosis and treatment.
    Journal
    |
    DNMT3A (DNA methyltransferase 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CXCL5 (Chemokine (C-X-C motif) ligand 5)
    11d
    Urinary Chemokines in the Diagnosis and Monitoring of Immune Checkpoint Inhibitor-Associated Nephritis. (PubMed, Int J Mol Sci)
    The decrease of CXCL9 and CXCL10 correlated with greater kidney function recovery at one-year follow-up. These molecules could serve as noninvasive biomarkers and may aid fine patient monitoring.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • IL6 (Interleukin 6) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • PD-L2 (Programmed Cell Death 1 Ligand 2) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • CCL2 (Chemokine (C-C motif) ligand 2) • CCL3 (C-C Motif Chemokine Ligand 3) • CXCL5 (Chemokine (C-X-C motif) ligand 5)
    19d
    Inflammatory profile associated with hyperglycemia in children with type 1 diabetes. (PubMed, J Diabetes Complications)
    A broad range of inflammatory mediators are correlated with HbA1c in children with T1D. These inflammatory changes precede development of T1D complications, suggesting that possible pathophysiologic involvement should be investigated.
    Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2 (Interleukin 2) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • MMP2 (Matrix metallopeptidase 2) • CCL2 (Chemokine (C-C motif) ligand 2) • IL18 (Interleukin 18) • CCL8 (C-C Motif Chemokine Ligand 8) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • CCL27 (C-C Motif Chemokine Ligand 27) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • IL13 (Interleukin 13) • IL21 (Interleukin 21) • IL4 (Interleukin 4) • MMP1 (Matrix metallopeptidase 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • IL33 (Interleukin 33) • LIF (LIF Interleukin 6 Family Cytokine)
    24d
    Dissection of Vitronectin-Regulated Secretome in Hepatocellular Carcinoma. (PubMed, J Proteome Res)
    Using Parallel Reaction Monitoring (PRM) proteomics, we validated that the pro-tumorigenic cytokines CXCL5 and CXCL8 were significantly decreased following VTN knockdown. These findings indicate that VTN promotes expression of cytokines involved in HCC progression, implicating autocrine and paracrine mechanisms in its tumor-promoting effects.
    Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL5 (Chemokine (C-X-C motif) ligand 5)
    25d
    WISP1 is the stromal-secreting oncoprotein via paracrine downregulation of NDRG1, KAI1, and Maspin in human bladder cancer cells. (PubMed, Transl Oncol)
    Results suggest that WISP1, a stroma-specific secreted protein, modulates the behavior of bladder stroma cells via autocrine signaling. WISP1 induces tumor growth of bladder carcinoma cells in an isoform-dependent manner via paracrine signaling, indicating that WISP1 may behave as a mediator linking diseases of the human bladder.
    Journal
    |
    IL6 (Interleukin 6) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • NDRG1 (N-Myc Downstream Regulated 1) • CTGF (Connective tissue growth factor)
    29d
    CXCL5/CXCR2 Axis Related to Neutrophilic Inflammation in Ulcerative Colitis: A Comprehensive Analysis Integrating eQTL, pQTL, and Transcriptome Data. (PubMed, Curr Med Chem)
    There is a significant association between CXCL5/CXCR2 and UC under the MR assumption, which is potentially linked with colonic chemotaxis and activation of neutrophils. These findings highlight the potential of CXCL5/CXCR2 as a therapeutic target for UC. However, future functional studies are needed to validate these findings and explore the exact mechanisms by which CXCL5/CXCR2 influences immune cell crosstalk in UC.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
    1m
    NR4A2 induces perineural invasion in head and neck squamous cell carcinoma and pancreatic ductal adenocarcinoma via CXCL5/CXCR2 signaling axis. (PubMed, Cancer Lett)
    Further treatment with CXCL5 ligand significantly induced neuritogenesis, while the neurite outgrowth was abrogated when cotreated with CXCR2 (receptor for CXCL5) inhibitor SCH527123...NR4A2 knockdown in UMSCC1 cells impaired tumor formation in vivo, and the xenograft tissues exhibited significant downregulation of CXCL5, providing direct in vivo evidence for the NR4A2-CXCL5 axis in tumor progression. NR4A2 is a key driver of CXCL5-mediated PNI and the NR4A2/CXCL5/CXCR2 signaling axis is a potential therapeutic target in HNSCC and PDAC.
    Journal
    |
    RAC1 (Rac Family Small GTPase 1) • CCL2 (Chemokine (C-C motif) ligand 2) • TIMP2 (TIMP Metallopeptidase Inhibitor 2) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • NR4A2 (Nuclear Receptor Subfamily 4 Group A Member 2)
    |
    navarixin (MK-7123)
    1m
    Osteochondrosis and osteomalacia are distinguished by inflammatory factors and metabolites. (PubMed, Medicine (Baltimore))
    Furthermore, TNFRSF9 is suggested as an upstream determinant of osteomalacia, with the AMP to glutamate ratio identified as a potential biomarker. These results underscore the importance of utilizing these cytokines and metabolites in clinical practice for distinguishing between osteochondrosis and osteomalacia, as well as for exploring potential therapeutic interventions.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF9 (TNF Receptor Superfamily Member 9) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • IL33 (Interleukin 33)